Esperion Therapeutics’ (ESPR) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $16.00 price objective on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Esperion Therapeutics’ Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.01) EPS.

Other equities analysts have also recently issued reports about the company. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. JMP Securities reiterated a “market outperform” rating and set a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Cantor Fitzgerald began coverage on shares of Esperion Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a research report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Hold” and an average price target of $6.75.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $1.59 on Tuesday. The stock has a market capitalization of $313.29 million, a price-to-earnings ratio of -2.48 and a beta of 1.01. Esperion Therapeutics has a 52-week low of $1.57 and a 52-week high of $3.94. The stock’s 50 day moving average price is $1.97 and its two-hundred day moving average price is $2.08.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Summit Financial LLC grew its position in shares of Esperion Therapeutics by 18.2% during the 4th quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 7,150 shares during the period. Foundations Investment Advisors LLC grew its position in shares of Esperion Therapeutics by 48.6% during the 4th quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 9,872 shares during the period. Invesco Ltd. grew its position in shares of Esperion Therapeutics by 15.5% during the 4th quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company’s stock valued at $215,000 after acquiring an additional 13,101 shares during the period. Two Sigma Advisers LP grew its position in shares of Esperion Therapeutics by 0.4% during the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock valued at $7,956,000 after acquiring an additional 16,100 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its position in shares of Esperion Therapeutics by 15.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 123,896 shares of the biopharmaceutical company’s stock valued at $273,000 after acquiring an additional 16,404 shares during the period. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.